Moreover, the combination of bortezomib, a proteasome inhibitor and FDA approved drug for multiple myeloma, with inhibition of SPHK2 synergistically increased ER stress and apoptosis [114]. The gene discussed is SPHK2; the disease is AL amyloidosis.